

Despite being an extremely rare and variable condition, Haberland syndrome has some distinctive clinical and radiological features. Both neurologists and radiologists should therefore evaluate these findings as a whole to diagnose the condition as early as possible.

## References

- López Pisón J, García Jiménez MC, Lafuente Hidalgo M, Pérez Delgado R, Monge Galindo L, Cabrerizo de Diago R, et al. Encefalopatías prenatales. Nuestra experiencia diagnóstica de 19 años. ¿Hasta dónde con los estudios bioquímicos y genéticos? *Neurología*. 2011;26:481–7.
- Haberland C, Perou M. Encephalocraniocutaneous lipomatosis. A new example of ectomesodermal dysgenesis. *Arch Neurol*. 1970;22:144–55.
- Sanchez NP, Rhodes AR, Mandell F, et al. Encephalocraniocutaneous lipomatosis: A new neurocutaneous syndrome. *Br J Dermatol*. 1981;104:89–96.
- Lachman RS, Taybi H. Taybi and Lachman's radiology of syndromes, metabolic disorders, and skeletal dysplasias. 5th ed. Philadelphia: Mosby Elsevier; 2007.
- Roszkowski M, Dabrowski D. Encephalo-cranio-cutaneous lipomatosis (ECCL) —Haberland syndrome. A case report with review of the literature. *Neurol Neurochir Pol*. 1997;31: 607–13.
- Fishman MA, Chang CSC, Miller JE. Encephalocraniocutaneous lipomatosis. *Paediatrics*. 1978;61:580–2.
- McCall S, Ramzy MI, Cure JK, Pai GS. Encephalocraniocutaneous lipomatosis and the Proteus syndrome: distinct entities with overlapping manifestations. *Am J Med Genet*. 1992;43: 662–8.

F.J. González Ortega\*, M. Céspedes Mas, F. Ramírez Garrido  
*Servicio de Radiodiagnóstico, Hospital Universitario San Cecilio, Granada, Spain*

\* Corresponding author.

E-mail address: colodrillo@gmail.com

(F.J. González Ortega).

2173-5808/

© 2016 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Emery-Dreifuss muscular dystrophy type 2: New de novo mutation in the lamin A/C gene<sup>☆</sup>



### Distrofia muscular de Emery-Dreifuss tipo 2: nueva mutación de novo en el gen la lamina A/C

Dear Editor,

Emery-Dreifuss muscular dystrophy (EDMD) is characterised by the following clinical triad: joint contractures beginning in childhood and initially affecting elbows, ankles, and neck; muscle weakness initially in a humero-peroneal distribution that subsequently extends to the scapular and pelvic girdle muscles; and cardiac manifestations (palpitations, syncope, heart failure, ventricular or supraventricular arrhythmias, conduction disorders, dilated/hypertrophic cardiomyopathy, and sudden death). Symptoms normally appear in the second decade of life or later.<sup>1–3</sup> Prevalence is estimated at 0.13 to 0.2 cases per 100 000 population.<sup>4</sup> To date, 3 genes responsible for the disease have been identified: *EMD* (encoding emerin); *FHL1* (encoding FHL1), both causing X-linked EDMD<sup>1,5–7</sup>; and *LMNA* (encoding lamin A and C), responsible for autosomal dominant EDMD (AD-EDMD) and autosomal recessive EDMD (AR-EDMD).<sup>1,2,8</sup> We present the case of a patient with AD-EDMD and a

heterozygous mutation in *LMNA*, c.1588C>T, which has never been described in the literature.

The patient came to our department due to muscular dystrophy which started when he was an infant; he had no relevant family history. During his first year of life he experienced difficulty maintaining the position of his head due to cervical hyperextension; he displayed toe walking, frequent falls, and showed a positive Gowers sign. A muscle enzyme test (CPK) conducted when he was 2 yielded normal results; the EMG study revealed an interference pattern with short, low-amplitude, and occasionally polyphasic potentials. Fibrillations at rest were also recorded. At the age of 4, our patient had lumbar hyperlordosis and irreducible equinovarus feet. By the age of 10, he had difficulty walking and needed a wheelchair due to muscle retractions and weakness at the scapular belt and pelvic girdle; he also experienced loss of strength in the upper limbs (2/5) and lower limbs (3/5). A muscle biopsy performed when he was 13 revealed nonspecific changes, including considerable variation in muscle fibre size. At the age of 19, he developed restrictive chronic respiratory failure secondary to chest deformities. When he was 29, he underwent pacemaker implantation due to complete atrioventricular block. Given a suspected case of EDMD with a lack of relevant family history, we sequenced the lamin A/C gene (*LMNA*). The gene was found to include the heterozygous variant c.1588C>T, leading to a missense mutation with substitution of p.Leu530Phe, resulting in an altered protein; the in silico analysis confirmed the pathogenicity of this mutation. Neither of the parents expressed this mutation; our patient was diagnosed with AD-EDMD. He developed ventricular tachycardias requiring the implantation of an automatic defibrillator. He died in his fourth decade due to pulmonary aspiration.

The variant found in our patient (c.1588C>T) has never been described in the literature. However, a similar variant (c.1589T>C) has been reported; this variant results in a

<sup>☆</sup> Please cite this article as: Ortiz Madinaveitia S, del Valle Sanchez M, Sagarra Mur D. Distrofia muscular de Emery-Dreifuss tipo 2: nueva mutación de novo en el gen la lamina A/C. *Neurología*. 2018;33:554–555.

missense mutation (p.Leu530Pro) and it is associated with AD-EDMD.<sup>9</sup> AD and X-linked variants are usually similar in terms of neuromuscular and cardiac manifestations.<sup>1,2,6,10</sup> However, there is no clear correlation between genotype and phenotype when the mutation affects the *LMNA* gene,<sup>1,2,11</sup> although some authors suggest that patients with missense mutations typically present early musculoskeletal changes.<sup>12</sup> In patients with EDMD, EMG studies usually reveal a myopathic pattern whereas results from nerve conduction studies are normal, as in our case. However, neuropathic patterns have been described in some cases of autosomal dominant and X-linked forms.<sup>13</sup> Muscle biopsy results normally reveal nonspecific myopathic/dystrophic changes, including changes in muscle fibre size; however, immunohistochemical studies can guide the diagnosis (this technique was not available when our patient underwent a biopsy).<sup>1</sup> In summary, we describe the case of a patient with the typical clinical triad of EDMD<sup>1,14</sup> and an autosomal dominant mutation not described to date. We should have a high level of clinical suspicion in cases of muscle dystrophy of unknown origin associated with contractures beginning in childhood despite the absence of cardiomyopathy, which typically appears at later stages of EDMD type 2.<sup>1,2</sup>

## Funding

This study has received no funding of any kind.

## References

- Bonne G, Leturcq F, Yaou RB. Emery-Dreifuss muscular dystrophy. In: GeneReviews; 2016. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1436/> [accessed 31.03.16].
- Bonne G, Mercuri E, Muchir A, Urtizberea A, Becane HM, Recan D, et al. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. *Ann Neurol*. 2000;48:170–80.
- Sanna T, Dello Russo A, Toniolo D, Vytopil M, Pelargonio G, de Martino G, et al. Cardiac features of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutations. *Eur Heart J*. 2003;24:2227–36.
- Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. *Brain*. 2009;132:3175–86.
- Gueneau L, Bertrand AT, Jais JP, Salih MA, Stojkovic T, Wehnert M, et al. Mutations of the *FHL1* gene cause Emery-Dreifuss muscular dystrophy. *Am J Hum Genet*. 2009;85:338–53.
- Manilal S, Recan D, Sewry CA, Hoeltzenbein M, Llense S, Leturcq F, et al. Mutations in Emery-Dreifuss muscular dystrophy and their effects on emerin protein expression. *Hum Mol Genet*. 1998;7:855–64.
- Ankala A, Kohn JN, Hegde A, Meka A, Ephrem CL, Askree SH, et al. Aberrant firing of replication origins potentially explains intragenic nonrecurrent rearrangements within genes, including the human *DMD* gene. *Genome Res*. 2012;22:25–34.
- Marsman RF, Bardai A, Postma AV, Res JC, Koopmann TT, Beekman L, et al. A complex double deletion in *LMNA* underlies progressive cardiac conduction disease, atrial arrhythmias, and sudden death. *Circ Cardiovasc Genet*. 2011;4:280–7.
- Bonne G, di Barletta MR, Varnous S, Bécane HM, Hammouda EH, Merlini L, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. *Nat Genet*. 1999;21:285–8.
- Cowling BS, Cottle DL, Wilding BR, D'Arcy CE, Mitchell CA, McGrath MJ. Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: a comprehensive review of the clinical, histological and pathological features. *Neuromuscul Disord*. 2011;21:237–51.
- Bertrand AT, Chikhaoui K, Yaou RB, Bonne G. Clinical and genetic heterogeneity in laminopathies. *Biochem Soc Trans*. 2011;39:1687–92.
- Benedetti S, Menditto I, Degano M, Rodolico C, Merlini L, D'Amico A, et al. Phenotypic clustering of lamin A/C mutations in neuromuscular patients. *Neurology*. 2007;69:1285–92.
- Walter MC, Witt TN, Weigel BS, Reilich P, Richard P, Pongratz D, et al. Deletion of the *LMNA* initiator codon leading to a neurogenic variant of autosomal dominant Emery-Dreifuss muscular dystrophy. *Neuromuscul Disord*. 2005;15:40–4.
- Emery AE. Emery-Dreifuss muscular dystrophy. *Neuromuscul Disord*. 2000;10:228–32.

S. Ortiz Madinaveitia<sup>a,\*</sup>, M. del Valle Sanchez<sup>b</sup>,  
D. Sagarra Mur<sup>c</sup>

<sup>a</sup> *Servicio de Pediatría, Hospital Santa Bárbara, Soria, Spain*

<sup>b</sup> *Servicio de Medicina Interna, Hospital Santa Bárbara, Soria, Spain*

<sup>c</sup> *Servicio de Neurología, Hospital Santa Bárbara, Soria, Spain*

\* Corresponding author.

E-mail address: [sortiz@saludcastillayleon.es](mailto:sortiz@saludcastillayleon.es)

(S. Ortiz Madinaveitia).

2173-5808/

© 2016 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This article is made available under the Elsevier license (<http://www.elsevier.com/open-access/userlicense/1.0/>).